Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A
Choose another version >>

Archived Clinical Summary

Chlamydial Infection: Screening

Originally published on: January 6, 2014

This recommendation statement is currently archived and inactive. It should be used for historical purposes only. Click here for copyright and source information .

Disclaimer:Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Archived: Clinical Summary of U.S. Preventive Services Task Force Recommendations

This document is a summary of the 2007 update of recommendations of the U.S. Preventive Services Task Force (USPSTF) on screening for chlamydial infection. This summary is intended for use by primary care clinicians.

For a summary of the evidence systematically reviewed in making these recommendations, the full supporting documents, go to

Select for copyright and source information.

Population Non-Pregnant Women Pregnant Women Men
24 years and younger 25 years and older 24 years and younger 25 years and older
Includes adolescents Not at increased risk At increased risk Includes adolescents Not at increased risk At increased risk
Recommendation A
Screen if Sexually Active
Screen if Sexually Active
No recommendation due to insufficient evidence1
Risk Assessment Age: Women and men aged 24 years and younger are at greatest risk.
History of: Previous Chlamydial infection or other sexually transmitted infections, new or multiple sexual partners, inconsistent condom use, sex work.
Demographics: African-Americans and Hispanic women and men have higher prevalence rates than the general population in many communities.
Screening Tests Nucleic acid amplification tests (NAATs) can identify chlamydial infection in asymptomatic women (non-pregnant and pregnant) and asymptomatic men. NAATs have high specificity and sensitivity and can be used with urine and vaginal swabs.
Screening Intervals Non-Pregnant Women
The optimal interval for screening is not known. The CDC recommends that women at increased risk be screened at least annually.2
Pregnant Women
For women 24 years and younger and older women at increased risk: Screen at the first prenatal visit.
For patients at continuing risk, or who are newly at risk: Screen in the 3rd trimester.
Not applicable
Treatment The Centers for Disease Control and Prevention has outlined appropriate treatment at: Test and/or treat partners of patients treated for Chlamydial infection.

1. Chlamydial infection results in few sequelae in men. Therefore, the major benefit of screening men would be to reduce the likelihood that infected and untreated men would pass the infection to sexual partners. There is no evidence that screening men reduces the long-term consequences of chlamydial infection in women. Because of this lack of evidence, the USPSTF was not able to assess the balance of benefits and harms, and concluded that the evidence is insufficient to recommend for or against routinely screening men.

2. Centers for Disease Control and Prevention, Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006. 55(No. RR-11).

This document is in the public domain within the United States.

Requests for linking or to incorporate content in electronic resources should be sent via the USPSTF contact form.

Source: U.S. Preventive Services Task Force. Screening for Chlamydial Infection: Clinical Summary of U.S. Preventive Services Task Force Recommendations. Ann Intern Med 2007;147(2):131.

Current as of: June 2007

Internet Citation: Clinical Summary: Chlamydial Infection: Screening. U.S. Preventive Services Task Force. October 2014.

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857